BRPI0514983A - combinação de um agonista do receptor 5-ht(1) e um ligante alfa-2-delta para tratamento da enxaqueca - Google Patents

combinação de um agonista do receptor 5-ht(1) e um ligante alfa-2-delta para tratamento da enxaqueca

Info

Publication number
BRPI0514983A
BRPI0514983A BRPI0514983-5A BRPI0514983A BRPI0514983A BR PI0514983 A BRPI0514983 A BR PI0514983A BR PI0514983 A BRPI0514983 A BR PI0514983A BR PI0514983 A BRPI0514983 A BR PI0514983A
Authority
BR
Brazil
Prior art keywords
combination
alpha
receptor agonist
delta ligand
treating migraine
Prior art date
Application number
BRPI0514983-5A
Other languages
English (en)
Inventor
Jayasena Hettiarachchi
Iradj Haji Mohamad Reza
Carolyn Rose Sikes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0419849.5A external-priority patent/GB0419849D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0514983A publication Critical patent/BRPI0514983A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMBINAçãO DE UM AGONISTA DO RECEPTOR 5-HT (1) E UM LIGANTE ALFA-2 -DELTA PAPA TRATAMENTO DA ENXAQUECA A presente invenção refere-se a uma combinação de 5 um agonista do receptor 5-HT~ 1B~, 5-HT~ lD~ ou 5-HT~ 1F~, e de um ligante alfa-2-delta. Uma tal combinação é de utilidade no tratamento da dor, particularmente, dor proveniente da enxaqueca.
BRPI0514983-5A 2004-09-07 2005-08-27 combinação de um agonista do receptor 5-ht(1) e um ligante alfa-2-delta para tratamento da enxaqueca BRPI0514983A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0419849.5A GB0419849D0 (en) 2004-09-07 2004-09-07 Pharmaceutical combination
US61460704P 2004-09-29 2004-09-29
PCT/IB2005/002684 WO2006027681A1 (en) 2004-09-07 2005-08-27 Combination of a 5-ht(1) receptor agonist and an alpha-2-delta ligand for the treatment of migraine

Publications (1)

Publication Number Publication Date
BRPI0514983A true BRPI0514983A (pt) 2008-07-01

Family

ID=35116045

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514983-5A BRPI0514983A (pt) 2004-09-07 2005-08-27 combinação de um agonista do receptor 5-ht(1) e um ligante alfa-2-delta para tratamento da enxaqueca

Country Status (6)

Country Link
EP (1) EP1791599A1 (pt)
JP (1) JP2008512436A (pt)
BR (1) BRPI0514983A (pt)
CA (1) CA2578990A1 (pt)
MX (1) MX2007002790A (pt)
WO (1) WO2006027681A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010046399A1 (en) * 2008-10-22 2010-04-29 Novartis Ag Combinations for the treatment of migraine
SI2627328T1 (sl) * 2010-10-15 2017-01-31 Contera Pharma Aps Kombinacije agonistov receptorjev serotonina za zdravljenje motenj premikanja
CN104411301B (zh) 2012-04-18 2018-02-06 康特拉医药公司 适于改善运动障碍治疗的口服药物配方
AU2017297718B2 (en) 2016-07-11 2023-06-08 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia
CA3157466A1 (en) * 2020-01-22 2021-07-29 Diana Sofia CHAPELA DUARTE PIRES Eletriptan hydrobromide for treatment of spinal cord injury and improvement of locomotor function

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ508491A (en) * 1998-07-09 2003-09-26 Warner Lambert Co Compositions comprising GABA analogs and a decongestant to relieve sinus headache pain
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations

Also Published As

Publication number Publication date
JP2008512436A (ja) 2008-04-24
CA2578990A1 (en) 2006-03-16
MX2007002790A (es) 2007-04-23
WO2006027681A1 (en) 2006-03-16
EP1791599A1 (en) 2007-06-06

Similar Documents

Publication Publication Date Title
BRPI0408902A (pt) composições de inibidores seletivos da ciclooxigenase-2 e agonistas de 5-ht 1b/1d para o tratamento e a prevenção de enxaqueca
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
TNSN07161A1 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
TW200730168A (en) Combination of an H3 antagonist/inverse agonist and an appetite suppressant
DE602005016601D1 (de) 5ht2c-rezeptor-modulator-zusammensetzungen und anwendungsverfahren
TW200640867A (en) Pyridine-3-carboxamide derivatives as CB1 inverse agonists
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
PH12015500576A1 (en) Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
EP2177224A3 (en) Agents for preventing and treating disorders involving modulation of the RyR receptors
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
SG155163A1 (en) Pharmacokinetically improved compounds
TNSN08396A1 (en) Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual
TNSN07111A1 (en) Preparation and use of biphenyl-4-yl- carbonylamino acid derivatives for the treatment of obesity.
NO20085338L (no) Substituerte 1,3-difenylpropanderivater, sammensetninger og anvendelser derav
MX2008009579A (es) Metodo para el tratamiento de dolor neuropatico.
TW200722083A (en) Combinations and methods of using an indolinone compound
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
MXPA05013016A (es) Gaboxadol para el tratamiento de la depresion y otros trastornos afectivos.
TW200740470A (en) Diclofenac formulations and methods of use
NO20076191L (no) Magnesiumsalter av HMG-COA reduktaseinhibitorer
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
BRPI0514983A (pt) combinação de um agonista do receptor 5-ht(1) e um ligante alfa-2-delta para tratamento da enxaqueca
TW200716088A (en) Formulations and methods for treating amyloidosis
DE602006014305D1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/404 (2006.01), A61P 25/06 (2006.01), A61K